Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
5106.00Today’s High
5106.0052W low
4636.6052W High
5642.80Open Price
5106.00Prev. Close
4935.5500Volume
6345.00Value
32397887.25Fundamentals
Market Cap Cr
8475.70
Price to Earnings
39.60
Price to Book Value
11.30
Dividend Yield
4.90
PE to Growth
-3.60
Op Revenue TTM Cr
1168.56
Net Profit TTM Cr
214.02
Cash From Operating Activity Cr
236.00
Return on Equity %
30.55
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
02 Jul, 2024
64.9
Week
75.8
Month
69.4
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
5112.07
PIVOT
First Resistance
5134.13
Second Resistance
5162.22
Third Resistance
5184.28
First Support
5083.98
Second Support
5061.92
Third Support
5033.83
Relative Strength Index
65.86
Money Flow Index
56.19
MACD
63.23
MACD Signal
58.89
Average True Range
100.51
Average Directional Index
33.19
Rate of Change (21)
8.62
Rate of Change (125)
3.2
Commodity Channel Index
168.3
Williams %R
-19.4
BETA
1 Month
0.14
3 Month
0.2
1 Year
0.2
3 Year
0.19
PRICE CHANGE ANALYSIS
↑ 1.63%
1 Week
Low
High
4965.15
5140.15
↑ 8.62%
1 Month
Low
High
4641.15
5150
↑ 7.26%
3 Months
Low
High
4636.55
5150
↑ 3.09%
6 Months
Low
High
4636.55
5642.85
↓ -2.83%
1 Year
Low
High
4636.55
5642.85
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 254.75 | 315.15 | 310.98 | 306.64 | 325.89 | 314.51 | 300.97 | 298.99 | 270.17 | 282.60 | 275.84 | |
| Operating Expenses Qtr | 185.04 | 208.32 | 216.27 | 255.96 | 243.39 | 199.59 | 206.73 | 236.12 | 199.05 | 216.06 | 194.73 | |
| Operating Profit Qtr | 67.44 | 101.65 | 88.66 | 45.22 | 79.66 | 110.38 | 90.82 | 59.04 | 68.77 | 61.84 | 78.07 | |
| EBIDT Qtr Cr | 69.71 | 106.83 | 94.71 | 50.68 | 84.63 | 114.92 | 94.24 | 62.14 | 71.12 | 66.54 | 81.11 | |
| Depreciation Qtr | 6.84 | 6.92 | 6.48 | 6.38 | 5.89 | 9.75 | 7.48 | 7.47 | 6.12 | 6.59 | 6.90 | |
| Net Profit Qtr | 46.56 | 72.07 | 65.57 | 29.82 | 59.19 | 76.80 | 63.66 | 41.19 | 51.16 | 44.84 | 55.37 | |
| Basic EPS Qtr | 28.00 | 43.40 | 39.50 | 17.96 | 35.70 | 46.30 | 38.30 | 24.80 | 30.82 | 27.00 | 33.40 |
| Indicator | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Dec 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1248.01 | 1127.60 | 1026.83 | 1424.75 | 974.54 | |
| Operating Expenses Annual Cr | 904.94 | 846.73 | 762.71 | 1040.45 | 723.02 | |
| Operating Profit Annual | 324.68 | 267.68 | 246.02 | 315.41 | 203.58 | |
| Operating Profit Margin Annual % | 26.02 | 23.74 | 23.96 | 22.14 | 20.89 | |
| Total Expenses Annual Cr | 933.81 | 874.23 | 793.55 | 1069.90 | 740.18 | |
| EBIDT Annual Cr | 343.07 | 280.87 | 264.12 | 384.30 | 251.52 | |
| EBIDT Annual margin % | 27.49 | 24.91 | 25.72 | 26.97 | 25.81 | |
| Depreciation | 28.10 | 27.08 | 30.04 | 29.45 | 17.16 | |
| PAT Before ExtraOrdinary Items Annual Cr | 229.47 | 192.52 | 176.80 | 254.08 | 158.76 | |
| Net Profit Annual | 229.47 | 192.52 | 176.80 | 254.08 | 158.76 | |
| Basic EPS Annual | 138.00 | 116.00 | 107.00 | 153.00 | 95.64 |
| Indicator | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Dec 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 750.89 | 616.49 | 703.71 | 906.34 | 816.81 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 46.40 | 41.40 | 43.48 | 42.06 | 27.34 | |
| Total Current Liabilities Annual Cr | 303.90 | 235.83 | 238.97 | 227.34 | 222.52 | |
| Total Capital Plus Liabilities Annual Cr | 1101.19 | 893.72 | 986.16 | 1175.74 | 1759.46 | |
| Fixed Assets Annual | 176.46 | 152.26 | 143.06 | 122.67 | 112.45 | |
| Total Non Current Assets Annual | 305.09 | 280.08 | 259.02 | 219.55 | 221.28 | |
| Total Current Assets Annual | 796.10 | 613.64 | 727.14 | 956.19 | 845.40 | |
| Total Assets Annual | 1101.19 | 893.72 | 986.16 | 1175.74 | 1066.68 | |
| Contingent Liabilities plus Commitments Annual Cr | 165.48 | 258.16 | 244.23 | 194.70 | - |
| Indicator | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Dec 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 236.00 | 169.52 | 247.26 | 235.37 | -130.38 | |
| Cash from Investing Activity Annual | -21.50 | -25.54 | -32.27 | 164.64 | 1269.72 | |
| Cash from Financing Annual Activity | -98.48 | -288.63 | -386.63 | -883.41 | -30.05 | |
| Net Cash Flow Annual | 116.02 | -144.65 | -171.64 | -483.40 | - |
| Indicator | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Dec 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 452.34 | 371.38 | 423.92 | 545.99 | 927.78 | |
| ROE Annual % | 30.55 | 31.22 | 25.12 | 28.03 | 54.45 | |
| ROCE Annual % | 39.50 | 38.57 | 31.32 | 37.41 | 9.68 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBDIT Annual Margin % | 27.90 | 25.20 | 26.18 | 28.34 | 27.14 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| ICICI PRUDENTIAL S&P BSE 500 ETF | 2.1 | 74517782 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| PROCTER AND GAMBLE OVERSEAS INDIA B.V. | 51.82 | 74517775 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMA | 3.98 | 74517781 |
| ICICI PRUDENTIAL S&P BSE 500 ETF | 2.1 | 74517782 |
| UTI - HEALTHCARE FUND | 1.64 | 74517783 |
| LIFE INSURANCE CORPORATION OF INDIA | 2.24 | 74517785 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| HUF | 0.62 | 74517794 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Feb 14, 2024 | 150 | SPECIAL | Feb 14, 2024 | Equity Share |
| Feb 14, 2024 | 50 | INTERIM | Feb 14, 2024 | Equity Share |
| Nov 23, 2023 | 50 | FINAL | - | Equity Share |
| Feb 13, 2023 | 45 | INTERIM | Feb 13, 2023 | Equity Share |
| Nov 15, 2022 | 11.5 | FINAL | - | Equity Share |
| May 12, 2022 | 41 | INTERIM | May 13, 2022 | Equity Share |
| Nov 02, 2021 | 90 | SPECIAL | - | Equity Share |
| Nov 02, 2021 | 40 | FINAL | - | Equity Share |
| Nov 18, 2020 | 188 | SPECIAL | - | Equity Share |
| Nov 18, 2020 | 42 | FINAL | - | Equity Share |
| May 23, 2019 | 416 | SPECIAL | - | Equity Share |
| May 23, 2019 | 24 | FINAL | - | Equity Share |
| May 21, 2018 | 15 | FINAL | - | Equity Share |
| May 25, 2017 | 11 | FINAL | - | Equity Share |
| Apr 22, 2016 | 7.5 | FINAL | - | Equity Share |
| Mar 30, 2015 | 6 | FINAL | - | Equity Share |
| Mar 10, 2014 | 8.5 | FINAL | - | Equity Share |
| Mar 07, 2013 | 2.5 | FINAL | - | Equity Share |
| Oct 22, 2010 | 95 | INTERIM | Oct 25, 2010 | Equity Share |
| Mar 18, 2010 | 20 | FINAL | - | Equity Share |
| Apr 06, 2009 | 17.5 | FINAL | - | Equity Share |
| Apr 04, 2008 | 10 | FINAL | - | Equity Share |
| Mar 21, 2007 | 10 | INTERIM | - | Equity Share |
| Mar 21, 2007 | 20 | FINAL | - | Equity Share |
| Apr 12, 2006 | 15 | FINAL | - | Equity Share |
| Jan 28, 2005 | 10 | FINAL | - | Equity Share |
| Feb 26, 2004 | 10 | FINAL | - | Equity Share |
| May 12, 2003 | 5 | FINAL | - | Equity Share |
| Feb 15, 2002 | - | FINAL | - | Equity Share |
| Jul 02, 2001 | - | INTERIM | Jul 16, 2001 | Equity Share |
| May 29, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| Aug 21, 2024 | Audited Results & Final Dividend | - |
| May 02, 2024 | Quarterly Results | - |
| Feb 06, 2024 | Quarterly Results & Interim Dividend | - |
| Nov 03, 2023 | Quarterly Results | - |
| Aug 23, 2023 | Audited Results & Final Dividend | - |
| May 15, 2023 | Quarterly Results | - |
| Feb 05, 2023 | Quarterly Results & Interim Dividend | - |
| Nov 11, 2022 | Quarterly Results | (Revised) |
| Aug 29, 2022 | Audited Results & Final Dividend | - |
| May 05, 2022 | Quarterly Results & Interim Dividend | - |
| Feb 09, 2022 | Quarterly Results | - |
| Nov 09, 2021 | Quarterly Results | - |
| Aug 26, 2021 | Audited Results & Final Dividend | - |
| May 06, 2021 | Quarterly Results | - |
| Feb 10, 2021 | Quarterly Results | - |
| Nov 11, 2020 | Quarterly Results | - |
| Sep 15, 2020 | Quarterly Results & Final Dividend | - |
| May 29, 2020 | Quarterly Results | - |
| Feb 07, 2020 | Quarterly Results | - |
| Nov 07, 2019 | Quarterly Results | - |
| Aug 08, 2019 | Quarterly Results & Interim Dividend | - |
| May 10, 2019 | Quarterly Results | - |
| Feb 27, 2019 | Audited Results & Final Dividend | - |
| Oct 30, 2018 | Quarterly Results | - |
| Aug 07, 2018 | Quarterly Results | - |
| Apr 27, 2018 | Quarterly Results | - |
| Mar 27, 2018 | Others | Appointed Mr. Milind Thatte, General Manager Healthcare, as an Additional Director and Managing Director of the Company, in place of Mr. Anand Nambiar, the present MD of the Company. |
| Feb 22, 2018 | Audited Results & Dividend | - |
| Nov 14, 2017 | Quarterly Results | - |
| Aug 07, 2017 | Quarterly Results | - |
| May 03, 2017 | Quarterly Results | - |
| Feb 27, 2017 | Audited Results & Dividend | - |
| Nov 11, 2016 | Quarterly Results | - |
| Jul 25, 2016 | Quarterly Results | - |
| May 12, 2016 | Quarterly Results | - |
| Apr 04, 2016 | Others | To change of Registrar to an Issue and Share Transfer Agent (RTA) from Sharepro Services (India) Private Limited to Karvy Computershare Private Limited. |
| Feb 26, 2016 | Audited Results & Dividend | - |
| Dec 21, 2015 | Shifting of Registered Office & Others | Policy on Determining and Disclosure of Material Events/Information as required under Reg. 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 effective December. |
| Oct 30, 2015 | Quarterly Results | - |
| Aug 12, 2015 | Quarterly Results | - |
| May 07, 2015 | Quarterly Results | - |
| Feb 05, 2015 | Audited Results & Dividend | for the year 31/12/2014 |
| Nov 13, 2014 | Quarterly Results | - |
| Aug 12, 2014 | Quarterly Results | - |
| Apr 30, 2014 | Quarterly Results | - |
| Jan 31, 2014 | Audited, Quarterly Results & Dividend | - |
| Oct 21, 2013 | Quarterly Results | - |
| Jul 29, 2013 | Quarterly Results | - |
| Apr 26, 2013 | Quarterly Results | - |
| Jan 30, 2013 | Audited Results & Dividend | - |
| Oct 22, 2012 | Quarterly Results | - |
| Jul 23, 2012 | To consider appointment of M.D. | inter alia, to consider appointment of Dr. Claus-Dieter Boedecker as M.D. of the Company w.e.f. August 01, 2012 in place of Dr. Marek Dziki whose term of appointment is expiring on July 31, 2012. |
| Apr 20, 2012 | Quarterly Results | First Quarter |
| Feb 28, 2012 | Audited Results | (Revised) |
| Nov 01, 2011 | Quarterly Results | - |
| Jul 26, 2011 | Quarterly Results | - |
| Apr 25, 2011 | Quarterly Results | - |
| Feb 08, 2011 | Audited & Quarterly Results | - |
| Oct 20, 2010 | Quarterly Results & Interim Dividend | - |
| Jul 28, 2010 | Quarterly Results | - |
| Apr 23, 2010 | Quarterly Results | - |
| Mar 29, 2010 | Appointment of Additional Director | The Board has approved the appointment of Mr. Pramod Pimplikar, VP -Technical Operations of the Company as Additional Director with effect from April 01, 2010. |
| Jan 22, 2010 | Audited Results & Dividend | - |
| Oct 15, 2009 | Quarterly Results | - |
| Jul 20, 2009 | Quarterly Results | - |
| May 20, 2009 | Buy Back of Shares | To approve a buy-back of its fully paid equity shares of the face value of Rs 10/- up to an amount of Rs 451.1 million being not more than 10% of the total paid up capital and free reserves. |
| Apr 20, 2009 | Quarterly Results | - |
| Feb 26, 2009 | Audited Results & Dividend | - |
| Oct 30, 2008 | Quarterly Results | - |
| Jul 30, 2008 | Quarterly Results | - |
| Apr 16, 2008 | Quarterly Results | - |
| Jan 30, 2008 | Audited Results & Dividend | - |
| Oct 18, 2007 | Quarterly Results | - |
| Jul 16, 2007 | Quarterly Results | - |
| Apr 20, 2007 | Quarterly Results | - |
| Mar 16, 2007 | Interim Dividend | (Revised) |
| Jan 22, 2007 | Accounts & Quarterly Results | - |
| Oct 19, 2006 | Quarterly Results | - |
| Jul 28, 2006 | Quarterly & Half Yearly Results | - |
| Apr 26, 2006 | Quarterly Results | - |
| Jan 27, 2006 | Accounts & Dividend | - |
| Jan 06, 2006 | Others | Consider inter alia, proposal to sell Companys Life Science and Analytics Division (excluding bulk drugs) to Merck Specialities Pvt. Ltd., a 100% Subsidiary of Merck KGaA, Germany. |
| Oct 29, 2005 | Quarterly Results | - |
| Jul 29, 2005 | Quarterly Results | - |
| Apr 13, 2005 | Quarterly Results | - |
| Jan 18, 2005 | Dividend & Accounts | - |
| Oct 28, 2004 | Quarterly Results | - |
| Jul 31, 2004 | Quarterly Results | - |
| Apr 19, 2004 | Quarterly Results | - |
| Jan 27, 2004 | Dividend & Accounts | - |
| Oct 15, 2003 | Quarterly Results | - |
| Jul 22, 2003 | Half Yearly Results | - |
| Apr 15, 2003 | Quarterly Results | - |
| Mar 20, 2003 | Dividend | Reconsider the rate of dividend recommended for the year 2002 in the Board Meeting 27.01.2003. |
| Jan 27, 2003 | Dividend & Others | Employees Stock Option Plan |
| Oct 29, 2002 | Quarterly Results | - |
| Jul 12, 2002 | Quarterly Results | - |
| Apr 18, 2002 | Quarterly Results | - |
| Mar 09, 2002 | Interim Dividend | - |
| Jan 29, 2002 | Accounts & Final Dividend | - |
| Oct 25, 2001 | Quarterly Results | - |
| Jul 18, 2001 | Quarterly Results | - |
| Jun 27, 2001 | Interim Dividend | - |
| Apr 27, 2001 | Quarterly Results | - |
| Feb 09, 2001 | Accounts | - |
| Oct 19, 2000 | Quarterly Results | - |
| Jul 21, 2000 | Half Yearly Results | - |
| Apr 24, 2000 | Quarterly Results & Interim Dividend | - |
| Feb 18, 2000 | Accounts | - |
| Oct 25, 1999 | Quarterly Results | - |
| Jul 24, 1999 | Quarterly Results | - |
| Jul 23, 1999 | Half Yearly Results | - |
| Apr 27, 1999 | Quarterly Results | - |
| Feb 27, 1999 | Accounts. | - |
| Oct 19, 1998 | Quarterly Results | - |
| Mar 13, 1998 | Accounts | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
27 Jun 2024
Procter & Gamble Health Ltd - 500126 - Closure of Trading Window
We would like to inform you that the Trading Window of the Company shall remain closed from July 1, 2024 until 48 hours from the publication of the audited financial results for the financial year ended June 30, 2024, as further detailed in enclosed letter.
27 Jun 2024
Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On August 21, 2024
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/08/2024 ,inter alia, to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, August 21, 2024, inter alia, to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30, 2024 and to consider recommendation of dividend (if any).
27 Jun 2024
Procter & Gamble Health Ltd - 500126 - Closure of Trading Window
Dear Sir, Please be informed that we have issued share certificate to our shareholder, as detailed in enclosed letter. Request you to kindly take note of the same.
12 Jun 2024
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
There has been a typographical error in the share certificate details mentioned in the earlier announcement of even date, in this regard find enclosed revised details with respect to loss of share certificates of shareholders of the Company as intimated by the RTA, Kfin technologies Limited.
12 Jun 2024
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Find enclosed details with respect to loss of share certificate(s) of shareholder(s) of the Company as intimated by the RTA, Kfin Technologies Ltd.
06 May 2024
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sir, Please be informed that we have issued duplicate share certificate to our shareholder as per attached letter. Kindly take the same on record.
03 May 2024
Q3FY24 Quarterly Result Announced for Procter & Gamble Health Ltd.
Pharmaceuticals company Procter & Gamble Health announced Q3FY24 results: Financial Highlights: Procter & Gamble Health Limited reported a decrease in sales and profit after tax for the Q3FY24. The total sales for the quarter were Rs 248 crore compared to Rs 316 crore a year ago, marking a downturn. Correspondingly, the Profit After Tax (PAT) also declined by 21% to Rs 46 crore. For the nine-month period ending March 31, 2024, P&G; Health's sales were recorded at Rs 852 crore, which exhibited a slight reduction from the previous year's sales of Rs 913 crore. The PAT for the nine-month period stood at 184 crore, experiencing a decrease from the Rs 200 crore reported in the prior year. Milind Thatte, Managing Director, P&G; Health India, said, “The Company’s continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter’s sales owing to the transition and optimization of trade management and inventory. However, we have seen sales recover in the months of March and April. We continue to drive operational efficiency and explore innovative solutions to accelerate category growth and demand for our portfolio of trusted, quality healthcare brands. The quarter also witnessed prescription growth and share gain for our doctor detailed products indicating a robust demand, and increased efforts to improve awareness of our self-select products. We remain confident in our integrated growth strategy of a focused product portfolio where performance drives brand choice, superiority, productivity, constructive disruption, and an agile and accountable organization structure to help drive growth and value creation,”he added. Result PDF
02 May 2024
Procter & Gamble Health Ltd - 500126 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Find enclosed press release on the unaudited financial results for the quarter ended March 31,2024
02 May 2024
Procter & Gamble Health Ltd - 500126 - Quarter Ended March 31,2024
Enclosed herewith are the unaudited financial results for the quarter ended March 31,2024 and the limited review report of the auditors thereon.
02 May 2024
Procter & Gamble Health Ltd - 500126 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended March 31,2024
Enclosed herewith are the unaudited financial results for the quarter ended March 31,2024 along with the limited review report of the auditors thereon.
